uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026)
uniQure (QURE) posted quarterly Net Income towards Common Stockholders of -$81.1 million for Q2 2026, down 114.9% year-over-year from $543.9 million in Q2 2025, and down 51.41% quarter-over-quarter from -$53.5 million in Q1 2026.
Analysis
uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
uniQure's Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$81.1 million for Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders fell 114.9% year-over-year to -$81.1 million; the TTM figure through Jun 2026 stood at -$196.7 million (up 1.16% YoY), while the FY2025 annual figure was -$199.0 million, up 16.94% from the prior year.
- Net Income towards Common Stockholders for Q2 2026 stood at -$81.1 million, down from -$53.5 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $18.4 million in Q4 2025, with the low at -$89.6 million in Q3 2023.
- The 5-year median for Net Income towards Common Stockholders is -$54.9 million (2024), against an average of -$52.9 million.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders plunged 1175.45% in 2023, then jumped 125.15% in 2025.
- uniQure's Net Income towards Common Stockholders stood at $6.8 million in 2022, then slumped by 1175.45% to -$73.2 million in 2023, then slipped by 0.08% to -$73.3 million in 2024, then jumped by 125.15% to $18.4 million in 2025, then sank by 539.89% to -$81.1 million in 2026.
- Business Quant data shows QURE's Net Income towards Common Stockholders at -$81.1 million in Q2 2026, -$53.5 million in Q1 2026, and $18.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -81.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -81.06 Mn |
| Mar 31, 2026 | -53.54 Mn |
| Dec 31, 2025 | 18.43 Mn |
| Sep 30, 2025 | -80.53 Mn |
| Jun 30, 2025 | -37.72 Mn |
| Mar 31, 2025 | -43.64 Mn |
| Dec 31, 2024 | -73.26 Mn |
| Sep 30, 2024 | -44.38 Mn |
| Jun 30, 2024 | -56.30 Mn |
| Mar 31, 2024 | -65.62 Mn |
| Dec 31, 2023 | -73.21 Mn |
| Sep 30, 2023 | -89.57 Mn |
| Jun 30, 2023 | -68.47 Mn |
| Mar 31, 2023 | -77.23 Mn |
| Dec 31, 2022 | 6.81 Mn |
| Sep 30, 2022 | -47.86 Mn |
| Jun 30, 2022 | -39.06 Mn |
| Mar 31, 2022 | -46.68 Mn |
| Dec 31, 2021 | 8.21 Mn |
| Sep 30, 2021 | -36.53 Mn |